Viral miRNA-mediated activation of hyaluronan production as a drug target against COVID-19

被引：0
|
作者：
Shuai Yang [1 ,2 ]
Lu Chen [1 ,2 ]
Ying Tong [1 ,2 ]
Wenqiang Yu [1 ,2 ]
机构：
[1] Laboratory of RNA Epigenetics, Institutes of Biomedical Sciences & Shanghai Public Health Clinical Center & Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute, Shanghai Medical College, Fudan University
[2] Shanghai Key Laboratory of Medical Epigenetics
来源：
ActaPharmaceuticaSinicaB | 2022年 / 12卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The global coronavirus disease 2019(COVID-19) pandemic has caused more than 6.1 million deaths until March 24, 2022, as reported by the World Health Organization(WHO). Recently,breakthrough infections have appeared in individuals fully vaccinated against SARS-Co V-21, which could be attributed to the rapid mutation of the RNA virus2. Currently, following the Delta variant, the Omicron variant of SARS-Co V-2 is increasingly becoming the dominant epidemic strain in the world.
引用
收藏
页码：3195 / 3197
页数：3
相关论文
共 50 条
  • [21] An effective drug against COVID-19: reality or dream?
    Yaghoubi, Atieh
    Amel Jamehdar, Saeid
    Movaqar, Aref
    Milani, Nasrin
    Soleimanpour, Saman
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2021, 15 (04) : 505 - 518
  • [22] Complement activation in patients with COVID-19: A novel therapeutic target
    Cugno, Massimo
    Meroni, Pier Luigi
    Gualtierotti, Roberta
    Griffini, Samantha
    Grovetti, Elena
    Torri, Adriana
    Panigada, Mauro
    Aliberti, Stefano
    Blasi, Francesco
    Tedesco, Francesco
    Peyvandi, Flora
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 146 (01) : 215 - +
  • [23] ACE2, a drug target for COVID-19 treatment?
    Liu, Yang
    Huang, Huilian
    IRISH JOURNAL OF MEDICAL SCIENCE, 2023, 192 (02) : 919 - 921
  • [24] Antibody production against COVID-19 in hemodialysis patients
    Gunal, Servin Yesil
    Eren, Didem
    Saatci, Esma
    Erdogan, Macide Deniz
    Gunal, Ali Ihsan
    REVISTA DE NEFROLOGIA DIALISIS Y TRASPLANTE, 2021, 41 (03): : 159 - 165
  • [25] DTSEA: A network-based drug target set enrichment analysis method for drug repurposing against COVID-19
    Su, Yinchun
    Wu, Jiashuo
    Li, Xiangmei
    Li, Ji
    Zhao, Xilong
    Pan, Bingyue
    Huang, Junling
    Kong, Qingfei
    Han, Junwei
    COMPUTERS IN BIOLOGY AND MEDICINE, 2023, 159
  • [26] ACE2, a drug target for COVID-19 treatment?
    Yang Liu
    Huilian Huang
    Irish Journal of Medical Science (1971 -), 2023, 192 : 919 - 921
  • [27] Viral Vector Vaccines Are Victorious Against COVID-19 in Patients with Cirrhosis
    Raphaella D. Ferreira
    Binu V. John
    Digestive Diseases and Sciences, 2023, 68 : 349 - 351
  • [28] Viral Vector Vaccines Are Victorious Against COVID-19 in Patients with Cirrhosis
    Ferreira, Raphaella D.
    John, Binu, V
    DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (02) : 349 - 351
  • [29] Early combined therapy for COVID-19 in immunocompromised patients: a promising approach against viral persistence and drug resistance
    Salvatore Rotundo
    Francesca Serapide
    Lavinia Berardelli
    Sara Palma Gullì
    Simona Mongiardi
    Maria Teresa Tassone
    Enrico Maria Trecarichi
    Alessandro Russo
    BMC Infectious Diseases, 25 (1)
  • [30] Molecules against COVID-19: An in Silico Approach for Drug Development
    Bharti R.
    Shukla S.K.
    Journal of Electronic Science and Technology, 2021, 19 (01) : 14 - 24
12345